Aim: B-type natriuretic peptides are recommended for evaluation of acute heart failure. Aim of this study was to identify predictors of pathologically elevated NT-pro-BNP in patients without acute heart failure.
Method: NT-pro-BNP was measured in 486 inpatients with cardiovascular disease and the association with clinical and laboratory parameters was examined. Elevated NT-pro-BNP was defined according to rule-in cut-off values for acute heart failure: 450 pg/ml for age <50 years, 900 pg/ml for 50-75 years and 1800 pg/ml for >75 years.
Results: Multivariate analysis of variables assessable without echocardiography revealed fibrinogen, albumin, atrial fibrillation, history of heart failure and diuretic use as independent predictors of pathological NT-pro-BNP. The odds for pathological NT-pro-BNP were 2.5, 8.8, 27 and 41 in the presence of 1, 2, 3 and 4/5 predictors, respectively. After adjusting for cardiac dysfunction, fibrinogen, albumin, history of heart failure and atrial fibrillation still remained significant.
Conclusion: Assessment of these parameters could help avoid wrong positive interpretation of NT-pro-BNP results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2007.07.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of lactate levels on admission in STEMI patients with cardiogenic shock treated with IMPELLA.
Heart Vessels
January 2025
Division of Cardiology, Mitsui Memorial Hospital, Kanda-Izumicho 1, Chiyoda-ku, Tokyo, 101-8643, Japan.
The concomitant use of IMPELLA and veno-arterial extracorporeal membrane oxygenation (V-A ECMO) (ECPELLA) has been increasingly used to treat severe cardiogenic shock. However, the relationship between severity of heart failure on admission and prognosis based on differences in the mechanical circulatory support (MCS) is not fully understood. This study evaluated the association between lactate levels on admission and clinical outcomes based on differences in MCS.
View Article and Find Full Text PDFDuration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors.
JNCI Cancer Spectr
January 2025
Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC.
Methods: Postmenopausal women diagnosed with hormone receptor-positive BC (n = 5,853) who used an AI were included.
Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.
Eur Heart J
January 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Background And Aims: The association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER) is unclear. This study aimed to examine the prognostic value of TR before and after M-TEER.
Methods: Patients in the OCEAN-Mitral registry were divided into four groups according to baseline and post-procedure echocardiographic assessments: no TR/no TR (no TR), no TR/significant TR (new-onset TR), significant TR/no TR (normalized TR), and significant TR/significant TR (residual TR) (all represents before/after M-TEER).
Commentary on 'Factors associated with patient activation in people with heart failure based on the individual and family self-management theory: a cross-sectional study'.
Eur J Cardiovasc Nurs
January 2025
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Viale Montpellier 1, 00133 Rome, Italy.
Discussing prognosis in heart failure: why do we leave it so late?
Eur J Cardiovasc Nurs
January 2025
Leeds Teaching Hospitals Trust, Great George Street, Leeds LS1 3EX, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!